$7B+
Reported transaction value
Including debt, according to reporting at the time of announcement.
Insights
PANTHERx Rare enters its next chapter
An important milestone for a healthcare platform built around the complex needs of rare disease patients.
The update
A new phase of ownership and growth
A Warburg Pincus-led investor group has agreed to acquire a controlling interest in PANTHERx Rare from Nautic Partners, General Atlantic and The Vistria Group.
The announced investment is intended to support continued innovation in rare disease care while preserving PANTHERx’s independent, patient-first model. Nautic Partners and management are expected to remain significant shareholders.
2026
Agreement announced
Announced July 13, subject to customary closing conditions and regulatory approvals.
2022
Board service
Matthew has served on the PANTHERx Rare Pharmacy board since 2022.
Why it matters
A milestone that reflects sustained value creation
PANTHERx has grown as a specialized platform at the intersection of patient access, complex therapy support and high-touch service. The proposed transaction recognizes the strength of that model and the team behind it.
Matthew’s connection
Board perspective grounded in healthcare operations
Matthew has served on the PANTHERx Rare Pharmacy board since 2022, bringing healthcare, strategy and operating experience to the company’s continued development.
The update is a useful example of the environments Ingenium understands: growth under investor ownership, strategic inflection points and the leadership decisions required to translate a strong model into durable value.
Explore Matthew’s experienceTransaction status
Announced, subject to closing conditions
The parties announced the agreement on July 13, 2026. The transaction remains subject to customary closing conditions and regulatory approvals. Financial terms were not disclosed by the parties; the value above reflects independent reporting and includes debt.
Read the official announcement